Blood and spinal fluid samples could unlock better tests for rare neurological diseases

NCT ID NCT05370079

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects blood and optional spinal fluid samples from 350 people with Parkinson's, ALS, glioblastoma, certain cancers, or rheumatoid arthritis. The goal is to find new genetic markers that could lead to better diagnostic tests for autoimmune encephalitis and paraneoplastic neurological syndromes, which are rare and hard to diagnose. Participants provide samples once, and no treatment is given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to more accurate diagnostic tests for rare neurological conditions like autoimmune encephalitis.
What could go wrong
This is an observational sample-collection study, not a treatment trial. It may not directly benefit participants and results may take years to apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER WITHOUT NEUROLOGICAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospices Civils de Lyon

    RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.